97-14106. New Animal Drugs For Use In Animal Feeds; Salinomycin, Roxarsone, Bacitracin Methylene Disalicylate  

  • [Federal Register Volume 62, Number 103 (Thursday, May 29, 1997)]
    [Rules and Regulations]
    [Pages 29014-29015]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 97-14106]
    
    
    -----------------------------------------------------------------------
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    
    Food and Drug Administration
    
    21 CFR Part 558
    
    
    New Animal Drugs For Use In Animal Feeds; Salinomycin, Roxarsone, 
    Bacitracin Methylene Disalicylate
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Final rule.
    
    -----------------------------------------------------------------------
    
    SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
    drug regulations to reflect approval of a supplemental new animal drug 
    application (NADA) filed by Hoffmann-La Roche, Inc. The supplemental 
    NADA provides for using approved single ingredient Type A medicated 
    articles to make Type C medicated broiler feeds containing salinomycin 
    with roxarsone and bacitracin methylene disalicylate.
    
    EFFECTIVE DATE: May 29, 1997
    
    FOR FURTHER INFORMATION CONTACT: Charles J. Andres, Center for 
    Veterinary Medicine (HFV-128), Food and Drug Administration, 7500 
    Standish Pl., Rockville, MD 20855, 301-594-2604.
    
    SUPPLEMENTARY INFORMATION: Hoffmann-La Roche, Inc., Nutley, NJ 07110-
    1199, filed supplemental NADA 135-321 which provides for use of single 
    ingredient Type A medicated articles containing Bio-Cox 
    (salinomycin as salinomycin sodium) 30 grams-per-pound (g/lb), 
    BMD (bacitracin methylene disalicylate) 30, 50, 60, or 75 g/
    lb bacitracin activity, 3-Nitro (roxarsone) 45.4, 90, or 227 
    g/lb roxarsone activity, to make Type C broiler chicken feeds 
    containing 40 to 60 g per ton (g/t) salinomycin sodium, 34.1 or 45.4 g/
    t roxarsone, and 4 to 50 g/t bacitracin methylene disalicylate, for 
    prevention of coccidiosis caused by Eimeria tenella, E. necatrix, E. 
    acervulina, E. maxima, E. brunetti, and E. mivati, including some field 
    strains of E. tenella that are more susceptible to roxarsone combined 
    with salinomycin than salinomycin alone; and for increased rate of 
    weight gain. Use of 34.1 or 45.4 g/t roxarsone is indicated to meet the 
    E. tenella challenge, which varies with environmental and management 
    conditions. The supplement is approved as of May 29, 1997. The basis of 
    approval is discussed in the freedom of information summary.
        Also, 21 CFR 558.550 is amended to redesignate existing paragraph 
    (b) as paragraph (d) and to add new paragraphs (b) and (c) to provide 
    for more uniform regulations and for future expansion. The regulations 
    are amended in newly redesignated paragraph (d) by adding new paragraph 
    (d)(1)(xvii) to reflect the approval.
        This approval is for use of three single ingredient Type A 
    medicated articles to make combination drug Type C medicated feeds. One 
    ingredient, roxarsone, is a Category II drug as defined in 21 CFR 
    558.3(b)(1)(ii). Under section 512(m) of the act (21 U.S.C. 360b(m)), 
    as amended by the Animal Drug Availability Act of 1996 (Pub. L. 104-
    250), use of salinomycin, roxarsone, and bacitracin methylene 
    disalicylate Type A medicated articles to make Type C medicated feeds 
    as provided in NADA 135-321 is limited to manufacture in a licensed 
    feed mill.
        In accordance with the freedom of information provisions of 21 CFR 
    part 20 and 514.11(e)(2)(ii), a summary of safety and effectiveness 
    data and information submitted to support approval of this application 
    may be seen in the Dockets Management Branch (HFA-305), Food and Drug 
    Administration, 12420 Parklawn Dr., rm. 1-23, Rockville, MD 20857, 
    between 9 a.m. and 4 p.m., Monday through Friday.
        Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and 
    Cosmetic Act, this approval for food-producing animals qualifies for 3 
    years of marketing exclusivity beginning May 29, 1997, because the 
    supplemental application contains substantial evidence of the 
    effectiveness of the drug involved, any studies of animal safety or, in 
    the case of food-producing animals, human food safety studies (other 
    than bioequivalence or residue studies) required for approval of the 
    application and conducted or sponsored by the applicant. The 3 years of 
    marketing exclusivity applies only to the new combination providing for 
    a 34.1 g/t level of roxarsone.
        The agency has determined under 21 CFR 25.24(d)(1)(ii) that this 
    action is of a type that does not individually or cumulatively have a 
    significant effect on the human environment. Therefore, neither an 
    environmental assessment nor an environmental impact statement is 
    required.
    
    List of Subjects in 21 CFR Part 558
    
        Animal drugs, Animal feeds.
        Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
    authority delegated to the Commissioner of Food and Drugs and 
    redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is 
    amended as follows:
    
    PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
    
        1. The authority citation for 21 CFR part 558 continues to read as 
    follows:
    
        Authority: Secs. 512, 701 of the Federal Food, Drug, and 
    Cosmetic Act (21 U.S.C. 360b, 371).
    
        2. Section 558.550 is amended by redesignating paragraph (b) as 
    paragraph (d), by adding and reserving new paragraphs (b) and (c), and 
    by adding new paragraph (d)(1)(xvii) to newly redesignated paragraph 
    (d) to read as follows:
    
    Sec. 558.550  Salinomycin.
    
    * * * * *
        (b) [Reserved]
        (c) [Reserved]
        (d) * * *
    
    [[Page 29015]]
    
        (1) * * *
        (xvii) (A) Amount per ton. Salinomycin 40 to 60 grams with 
    roxarsone 34.1 or 45.4 grams and bacitracin methylene disalicylate 4 to 
    50 grams.
        (B) Indications for use. For the prevention of coccidiosis caused 
    by Eimeria tenella, E. necatrix, E. acervulina, E. maxima, E. brunetti, 
    and E. mivati, including some field strains of E. tenella that are more 
    susceptible to roxarsone combined with salinomycin than to salinomycin 
    alone; for increased rate of weight gain. Use of 34.1 or 45.4 grams per 
    ton roxarsone is indicated to meet the E. tenella challenge which 
    varies with environmental and management conditions.
        (C) Limitations. Feed continuously as sole ration. Use as sole 
    source of organic arsenic. Not approved for use with pellet binders. Do 
    not feed to laying chickens. May be fatal if accidentally fed to adult 
    turkeys or horses. Poultry should have access to drinking water at all 
    times. Overdosage or lack of water may result in leg weakness or 
    paralysis. Withdraw 5 days before slaughter. Salinomycin as provided by 
    No. 000004 in Sec. 510.600(c) of this chapter. Roxarsone and bacitracin 
    as provided by No. 046573 in Sec. 510.600(c) of this chapter.
    * * * * *
    
        Dated: May 16, 1997.
     Robert C. Livingston,
     Director, Office of New Animal Drug Evaluation, Center for Veterinary 
    Medicine.
    [FR Doc. 97-14106 Filed 5-28-97; 8:45 am]
    BILLING CODE 4160-01-F
    
    
    

Document Information

Effective Date:
5/29/1997
Published:
05/29/1997
Department:
Food and Drug Administration
Entry Type:
Rule
Action:
Final rule.
Document Number:
97-14106
Dates:
May 29, 1997
Pages:
29014-29015 (2 pages)
PDF File:
97-14106.pdf
CFR: (1)
21 CFR 558.550